

March 13, 2018

Update March 2018

Dear Participants of the Rome High-Level Dialogue on Pediatric Formulations and Diagnostics,

Please find below the second brief summary of recent activities reported to us by the partners of the AIDS Free Working Group. Again, we would appreciate if you could keep us informed of any additional or planned activities so we may continue to report on them to the wider group.

FOCUS

- Action 1: Two webinars were held on Feb 5th by ILF/IAS in collaboration with WHO to disseminate the key outcomes of the PADO3 review to manufacturers and key stakeholder. Recordings and slides from webinars are available from ILF/IAS - <http://www.iasociety.org/HIV-Programmes/Programmes/Industry-Liaison-Forum/Events/ILF-Webinar-Report-back-on-PADO-3-review> . A summary report on the PADO3 review (held December, 12 2017) was sent to representatives from pharmaceutical companies and to PADO members which include key stakeholders, regulators and key funders. The meeting report is available for dissemination (see document PADO3 review summary).
- Action 3: PAWG bi-monthly meetings for 2018 restarted on February 12th, 2018. A follow-up call with Gilead is being planned to review implementation of their paediatric plan for TAF.
- Action 5: PENTA-Id and IMPAACT research networks have disseminated the Rome Action Plan to their members which is being considered for planning of future research projects.

ACCELERATE

- Action 19: IMPAACT and PENTA-Id are continuing collaborative work on the P1093 and ODYSSEY studies to expedite the determination of appropriate dosing for DTG in children below 30 kg. Both studies are investigating WHO weight bands- based dosing.
 - Action 21: UNITAID continues to support acceleration of the development and introduction of priority products. Efforts are ongoing to plan for facilitating rapid introduction of paediatric DTG in early adopting countries, leveraging the Optimal ARV Project in collaboration with CHAI.
 - Action 24: PAWG is developing a toolkit to support manufactures and stakeholders involved in pediatric ARV development to ensure accelerated research, development, and introduction of priority pediatric formulations. A first draft of the toolkit, developed by WHO in collaboration with UNITAID, IMPAACT, PENTA-Id and other partners is been shared with manufactures and regulators for review, and the final version will be made available in July 2018.
 - Action 27, 28 and Individual Commitment 10:
1. The Global Network of People Living with HIV (GNP+) launched a survey, The State of People Living with HIV at the end of 2017. This survey included questions on infants and childrens' early diagnoses and optimal HIV treatment and care in their country as

well as, information regarding stock outs of ARVs. Results of the survey are being analysed. GNP+ is planning to release the results at AIDS 2018.

2. GNP+ launched a new webinar series to provide treatment updates to people living with HIV. The first webinar focused on access to dolutegravir (DTG) and viral resistance to first-line ARVs (2 March). Access to paediatric versions of DTG was discussed. The DTG webinar recording is now available at www.gnpplus.net/civil-society-speaks-fighting-for-universal-access-to-dolutegravir-dtg/

COLLABORATE

- Action 35: The Free to Shine Campaign was launched by the Organization of African First Ladies Against HIV/AIDS (OAFLA) and the African Union on the sidelines of the 30th Ordinary Session of the African Union in Addis Ababa, Ethiopia (January 29). UNAIDS, WHO, Abbott, EGPAF, United Nations Children's Fund, UNDP and AIDS Accountability International, are partners in supporting the Campaign. UNAIDS has also instructed their country offices to support the in-country offices of the First the Lady to establish teams that will plan national activities and rapidly move the Free to Shine Campaign forward. http://www.unaids.org/en/resources/presscentre/featurestories/2018/february/20180106_OAFLA
- Action 40: GAP-f will continue to map the partners' landscape outside of HIV, and is developing an updated concept note and business plan to be released by WAC 2018. A website is being established to facilitate the sharing of resources on pediatric formulation research, development, and introduction.
- Action 41: PEPFAR organized a technical meeting in early February to share best practices and discuss new strategies for identifying children living with HIV; in particular, finding well children and looking beyond traditional, facility-based settings. PEPFAR plans to convene a technical consultation on diagnostics for end March. WHO is organizing a follow-up diagnostics meeting during AMDS (April 19-20) A concept paper for the diagnostics consultation has been developed by partners within the AIDS Free Working Group; plans for the consultations and preparatory meetings are ongoing.

Best regards,
Gottfried Hirnschall, WHO and Chip Lyons, EGPAF
Co-Chairs, AIDS Free Working Group